"Digoxin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666)
| Descriptor ID |
D004077
|
| MeSH Number(s) |
D04.210.500.155.580.130.500.436 D04.210.500.155.580.130.688 D09.408.180.261.436
|
| Concept/Terms |
Digoxine Nativelle- Digoxine Nativelle
- Nativelle, Digoxine
- Hemigoxine Nativelle
- Nativelle, Hemigoxine
Lanoxin- Lanoxin
- Lanoxin-PG
- Lanoxin PG
- Lenoxin
|
Below are MeSH descriptors whose meaning is more general than "Digoxin".
Below are MeSH descriptors whose meaning is more specific than "Digoxin".
This graph shows the total number of publications written about "Digoxin" by people in this website by year, and whether "Digoxin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 2 | 0 | 2 |
| 2000 | 3 | 0 | 3 |
| 2004 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 2 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Digoxin" by people in Profiles.
-
Mason JM, Krenz JR, Koehl JL, Fuh L, Nagurney JT, Wilcox SR, Hayes BD. Amiodarone versus digoxin for acute rate control of atrial fibrillation in the emergency department. Am J Emerg Med. 2022 12; 62:133-135.
-
Stewart JM, Warsy IA, Visintainer P, Terilli C, Medow MS. Supine Parasympathetic Withdrawal and Upright Sympathetic Activation Underly Abnormalities of the Baroreflex in Postural Tachycardia Syndrome: Effects of Pyridostigmine and Digoxin. Hypertension. 2021 04; 77(4):1234-1244.
-
Bosch NA, Rucci JM, Massaro JM, Winter MR, Quinn EK, Chon KH, McManus DD, Walkey AJ. Comparative Effectiveness of Heart Rate Control Medications for the Treatment of Sepsis-Associated Atrial Fibrillation. Chest. 2021 04; 159(4):1452-1459.
-
Cordeiro N, Gupta SS, Lindsay D, Seneviratne C, Kulbak G, Kupfer Y. Midodrine: Associated Bradycardia. Am J Ther. 2019 Sep/Oct; 26(5):e655-e656.
-
Al-Khateeb M, Qureshi WT, Odeh R, Ahmed AM, Sakr S, Elshawi R, Bdeir MB, Al-Mallah MH. The impact of digoxin on mortality in patients with chronic systolic heart failure: A propensity-matched cohort study. Int J Cardiol. 2017 Feb 01; 228:214-218.
-
Chiu DK, Xu IM, Lai RK, Tse AP, Wei LL, Koh HY, Li LL, Lee D, Lo RC, Wong CM, Ng IO, Wong CC. Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26. Hepatology. 2016 09; 64(3):797-813.
-
Qureshi W, O'Neal WT, Soliman EZ, Al-Mallah MH. Systematic review and meta-analysis of mortality and digoxin use in atrial fibrillation. Cardiol J. 2016; 23(3):333-43.
-
Hu JJ, Yin Z, Shen WL, Xie YB, Zhu T, Lu P, Cai YZ, Kong MJ, Heng BC, Zhou YT, Chen WS, Chen X, Ouyang HW. Pharmacological Regulation of In Situ Tissue Stem Cells Differentiation for Soft Tissue Calcification Treatment. Stem Cells. 2016 Apr; 34(4):1083-96.
-
Walkey AJ, Evans SR, Winter MR, Benjamin EJ. Practice Patterns and Outcomes of Treatments for Atrial Fibrillation During Sepsis: A Propensity-Matched Cohort Study. Chest. 2016 Jan; 149(1):74-83.
-
Temtanakitpaisan Y, Kilari S, Damrongwatanasuk R. Use of digoxin in chronic systolic heart failure in current era. Am J Med. 2015 Jan; 128(1):e17.